

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In Application of:  
Florence GUIMBERTEAU *et al.*

Application No.: 10/522,252

Confirmation No.: 8812

Filed: February 15, 2006

Art Unit: 1618

For: ORAL PHARMACEUTICAL FORMULATION      Examiner: N. Ebrahim  
IN THE FORM OF A PLURALITY OF  
MICROCAPSULES FOR PROLONGED  
RELEASE OF ACTIVE PRINCIPLE(S) WITH  
LOW SOLUBILITY

---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be considered for this application.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents, and U.S. patent applications. Applicants submit copies of foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h),

the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Credit Card in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed with this submission (or with any paper filed in this application by this firm) to our Deposit Account No. 50-2228, under Order No. 022290.0123PTUS, from which the undersigned is authorized to draw.

Dated: February 3, 2010

Respectfully submitted,

By           /Lacy L. Kolo/            
Lacy L. Kolo  
Registration No.: 55,340  
PATTON BOGGS LLP  
8484 Westpark Drive, 9th Floor  
McLean, Virginia 22102  
(703) 744-8029  
(703) 744-8001 (Fax)  
Attorney for Applicants